fiercebiotech.com
Link authority for fiercebiotech.com (registrable domain: fiercebiotech.com) from the Common Crawl web graph: PageRank and harmonic centrality history since 2017, current scores, and the site's top backlink sources.
Web-graph authority (0-100)
Domain scores measure fiercebiotech.com as a whole: every subdomain's links rolled up into one node of Common Crawl's domain-level web graph. Host scores measure the exact hostname fiercebiotech.com. WWW scores cover the www variant of that hostname, which the graph tracks as its own entry since January 2026 (before that, www and bare host were merged). A big gap between domain and host usually means the domain's authority lives on other subdomains. PageRank is link-endorsement authority: how much weight the sites linking here carry themselves. Harmonic centrality measures reach: how close this site sits to the rest of the web when following links, which favors broadly connected sites over ones boosted by a few heavy linkers. All are normalized 0 to 100 within each crawl snapshot; a dash means that series does not exist for this site.
Homepage
What fiercebiotech.com presents on its own homepage: the page title, description, and the social share markup it publishes. Pulled from https://www.fiercebiotech.com.
| Title | Fierce Biotech News & Reports |
|---|---|
| Description | Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on Fierce Biotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. |
| OG Title | Fierce Biotech |
Social accounts and contact points
Where this site maintains a presence and every reachable route its homepage exposes: social accounts, contact pages, addresses, and content feeds.
| fierce-biotech (business) | |
| fiercebiotech | |
| X | fiercebiotech |
| Feeds | https://www.fiercebiotech.com/rss/Fierce%20Biotech%20Homepage/xml |
|---|
Structured data (JSON-LD)
The schema.org markup this homepage publishes: the machine-readable identity search engines and AI systems read. Types found: ItemList, WebSite, Organization.
JSON-LD block (5,717 bytes)
{"@context":"https://schema.org/","@type":"ItemList","url":"https://www.fiercebiotech.com/fierce-biotech-homepage","numberOfItems":10,"itemListElement":[{"@type":"ListItem","position":1,"item":{"@type":"Article","url":"https://www.fiercebiotech.com/sponsored/understanding-agentic-ai-clinical-development","name":"Understanding Agentic AI in Clinical Development","description":"Earlier this year, my colleague Matt Harrington suggested that clinical leaders should stop asking whether their organizations have an \u201cAI strategy\u201d, not because strategy doesn\u2019t matter, but because the question often produces the wrong conversation.","image":"https://qtxasset.com/quartz/qcloud5/media/image/shutterstock_2729915667.png?VersionId=yRMfXRUOgbBbxBEI7CEK3__drIhnWjgd"}},{"@type":"ListItem","position":2,"item":{"@type":"Article","url":"https://www.fiercebiotech.com/biotech/dimerix-snaps-missions-stalled-phase-2-ready-kidney-disease-candidate-5m-upfront","name":"Dimerix snaps up Mission\u2019s stalled, phase 2-ready kidney disease candidate in $292M deal","description":"Dimerix is Mission paying $5 million upfront and committing up to $287 million in milestones for the phase 2-ready acute kidney injury asset.","image":"https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1496124491.jpg?VersionId=732gAQPbikEB4qbY.tIbbPZqc2fQC57E"}},{"@type":"ListItem","position":3,"item":{"@type":"Article","url":"https://www.fiercebiotech.com/biotech/takedas-zasocitinib-proves-top-notch-difficult-treat-psoriasis-phase-3-update","name":"Takeda\u2019s zasocitinib proves \u2018top-notch\u2019 for difficult-to-treat psoriasis in phase 3 update","description":"Takeda demonstrated the once-daily pill was able to clear or almost clear psoriasis of the scalp in 75% of patients. ","image":"https://qtxasset.com/quartz/qcloud5/media/image/IMG_0609.jpg?VersionId=dygDRlklYc_F5Xmm5LzL4CszbFlM1MIN"}},{"@type":"ListItem","position":4,"item":{"@type":"Article","url":"https://www.fiercebiotech.com/research/nobel-laureate-jennifer-doudna-enters-ai-protein-design-arena","name":"Nobel Laureate Jennifer Doudna enters AI protein design arena","description":"In a new paper, Doudna\u2019s team described a new platform for generating novel gene editing enzymes.","image":"https://qtxasset.com/quartz/qcloud5/media/image/jennifer_doudna.jpg?VersionId=NQ_s0dk.ENw1eIQ6DpTbsuDan7C5qe.j"}},{"@type":"ListItem","position":5,"item":{"@type":"Article","url":"https://www.fiercebiotech.com/research/axioms-wharton-jelly-stem-cell-therapy-posts-positive-phase-1-data-newborn-brain-injury","name":"Why Axiom hopes it\u2019s \u2018solved 2 major potholes\u2019 that have hurt other stem cell biotechs","description":"Axiom's experimental stem cell therapy demonstrated a 0% mortality rate over two years in potentially fatal newborn neurological diseases.","image":"https://qtxasset.com/quartz/qcloud5/media/image/umbilical_cord_stem_cells.jpg?VersionId=G1UrJ6ms0S2rK_ome0r.ytqn436clAw2"}},{"@type":"ListItem","position":6,"item":{"@type":"Article","url":"https://www.fiercebiotech.com/biotech/racing-takeda-innocare-reports-tyk2-inhibitor-win-phase-2-vitiligo-trial","name":"Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trial","description":"A phase 2 trial of soficitinib in vitiligo hit its primary endpoint, clearing the Chinese biotech to advance into the phase 3 part of the study.\r\n","image":"https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-2188975118.jpg?VersionId=yAy0GjPitTy5Z31pMTB7wr2NocYe5UjM"}},{"@type":"ListItem","position":7,"item":{"@type":"Article","url":"https://www.fiercebiotech.com/biotech/eli-lilly-inks-28b-ataibeckley-buyout-challenge-jj-psychedelic-mental-health-market","name":"Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental health market","description":"Continuing its takeover spree, Lilly is moving into a psychedelic mental health sector targeted by companies including Johnson & Johnson.","image":"https://qtxasset.com/quartz/qcloud5/media/image/LILLYSIGN.jpg?VersionId=YAjx95URbeDvZm3b4yvFa.Dr50m_kl9S"}},{"@type":"ListItem","position":8,"item":{"@type":"Article","url":"https://www.fiercebiotech.com/biotech/vogenx-joins-ipo-queue-fund-phase-2-stage-metabolic-drug","name":"Vogenx joins the IPO queue to fund phase 2-stage metabolic drug","description":"Vogenx has joined the growing queue for the Nasdaq, as the metabolic biotech eyes an IPO to fund its SGLT1 inhibitor.","image":"https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-502001684.jpg?VersionId=I2Rgu0ckI3Tp02ilr7awmna5nQpUbZ8G"}},{"@type":"ListItem","position":9,"item":{"@type":"Article","url":"https://www.fiercebiotech.com/biotech/braveheart-aims-freedom-ipo-support-hengrui-licensed-cardio-asset","name":"Braveheart aims for freedom with IPO to support Hengrui-licensed cardio asset","description":"Braveheart Bio isn\u2019t letting Big Pharma take its freedom anytime soon as it aims for a Nasdaq listing to move its phase 3 cardiovascular drug forward.","image":"https://qtxasset.com/quartz/qcloud5/media/image/gettyimages-2175729486.jpg?VersionId=TcFLnOD3bXC5.5Uj9tko_cs8F0LhDjC9"}},{"@type":"ListItem","position":10,"item":{"@type":"Article","url":"https://www.fiercebiotech.com/biotech/advancell-flush-315m-raise-ready-put-radiotherapy-pedal-metal","name":"Big Pharma-backed AdvanCell, flush with $315M series D, ready to put radiotherapy pedal to the metal","description":"With its new cash in hand, AdvanCell is positioned to stake its own claim in the surging field with a novel isotope, lead-212.","image":"https://qtxasset.com/quartz/qcloud5/media/image/gettyimages-2238906519.jpg?VersionId=oYFoAresY5vq3hzUnfG0pPH8LIukVL.e"}}]}JSON-LD block (298 bytes)
{"@context":"http://schema.org","@type":"WebSite","name":"Fierce Biotech","url":"https://www.fiercebiotech.com/","potentialAction":{"@type":"SearchAction","target":"https://www.fiercebiotech.com/search-results?fulltext_search={search_term_string}","query-input":"required name=search_term_string"}}JSON-LD block (1,427 bytes)
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "Organization",
"sameAs": [
"https://twitter.com/fiercebiotech",
"https://www.linkedin.com/showcase/fierce-biotech/",
"https://www.facebook.com/fiercebiotech/"
],
"name": "Fierce Biotech",
"url": "https://www.fiercebiotech.com/",
"logo": {
"@type": "ImageObject",
"url": "https://qtxasset.com/quartz/qcloud5/logos/Fierce%20Biotech%20Mix%20Logo.svg"
},
"image": {
"@type": "ImageObject",
"url": "https://qtxasset.com/quartz/qcloud5/logos/Fierce%20Biotech%20Mix%20Logo.svg"
},
"memberOf": {
"@type": "Organization",
"name": "Questex",
"url": "https://questex.com",
"telephone": "888.552.4346 +1.212.895.8200",
"address": {
"@type": "PostalAddress",
"streetAddress": [
"1111B S Governors Ave",
"STE 25792"
],
"addressLocality": "Dover",
"addressRegion": "DE",
"postalCode": "19904",
"addressCountry": "US"
}
}
}
]
}Authority over time
Every Common Crawl web-graph release since 2017, roughly quarterly. The domain series goes back to 2017; Common Crawl only began publishing the host-level graph in 2020, so host lines start there. Click a legend entry to show or hide that line. Flat lines are normal for established sites; watch for sustained rises or drops, which track real gains or losses in who links here.
A note on www: through the end of 2025 the source web graph merged www and non-www hostnames into the bare name, so one host line covers both. Starting in January 2026 the graph splits them into separate entries, which is why www can carry its own scores going forward.
Backlink counts
Unique linking domains seen in Common Crawl's link graphs. This is a different dataset than the 0-100 authority scores above: these are raw counts, host-level for fiercebiotech.com and domain-level for fiercebiotech.com with all its subdomains combined. Common Crawl covers a large sample of the web, not all of it, so treat counts as comparable between sites rather than absolute totals.
Top backlinks in the domain graph
Common Crawl publishes two link graphs. The DOMAIN graph connects whole domains: every link from any page of one domain to any page of another. This table shows the highest-authority domains linking to fiercebiotech.com (including its subdomains), ranked by the linker's PageRank. The table shows the top 1,000; the download carries the full stored list (up to 10,000 linkers) as JSON. Click a linker for its own site profile.
Top backlinks in the host graph
The HOST graph connects exact hostnames, so subdomains count separately. This table shows the highest-authority hosts linking to fiercebiotech.com specifically, ranked by the linker's PageRank. The table shows the top 48; the download carries the full stored list (up to 10,000 linkers) as JSON. Click a linker for its own site profile.